“We made a dual-targeted nanoparticle,” said Dr. Shanta Dhar, assistant director of Technology and Innovation at Sylvester Comprehensive Cancer Center. “The first targeting is needed to get it through the gut barrier, and the second targeting takes it to the prostate. The beauty is, now we can deliver a chemotherapeutic orally, which is usually never done. And by targeting the prostate, we can reduce kidney and liver toxicity and the risk of peripheral neuropathy.”